Partner Therapeutics Reports P-II (eNRGy) Post-Hoc Results on Zenocutuzumab for NRG1+ NSCLC

Why It Matters

The data suggest zenocutuzumab can provide durable disease control even after conventional progression, addressing a critical unmet need for patients with rare NRG1‑fusion NSCLC and potentially reshaping treatment sequencing strategies.

Key Takeaways

• 27 NRG1+ NSCLC patients received ≥3 zenocutuzumab doses
• 81% experienced oligoprogression, extending median exposure to ~10 months
• 22% continued therapy after local lesion management
• One patient remained on treatment for ~4 years
• Post‑progression benefit suggests durable disease control

Pulse Analysis

NRG1 gene fusions, though rare, represent an actionable oncogenic driver in a subset of non‑small cell lung cancer (NSCLC) patients who have limited targeted options. Zenocutuzumab, a bispecific antibody that simultaneously blocks HER3 and the NRG1 ligand, was granted accelerated approval based on early‑phase activity. The eNRGy study, now enriched with post‑hoc analyses, offers a deeper look at how the drug performs once conventional radiographic progression is observed, a scenario where most targeted agents lose efficacy and clinicians must switch to chemotherapy or immunotherapy.

The post‑hoc cohort revealed that 81% of patients experienced oligoprogression—a pattern where disease advances at a few isolated sites—allowing continued systemic control with zenocutuzumab. Median exposure rose to roughly ten months, a notable increase over the pre‑progression median of seven months, and a subset of patients remained on therapy for years. This durability mirrors emerging evidence from other targeted therapies, such as EGFR and ALK inhibitors, where local ablative treatments combined with continued drug exposure can prolong benefit. The findings underscore the importance of integrating local lesion management with systemic therapy to maximize patient outcomes in molecularly defined lung cancer.

From a commercial perspective, these results could strengthen Partner Therapeutics’ positioning of Bizengri in a niche yet growing market. Demonstrating efficacy beyond progression may support broader label claims, facilitate reimbursement discussions, and attract partnership interest for combination strategies. Moreover, the data provide a compelling narrative for investors, highlighting the company’s ability to generate meaningful clinical insights from relatively small patient cohorts, a critical factor as the oncology landscape increasingly values precision and durability of response.